OBJECTIVE: To explore the prevalence and discontinuation of dispensed medications for attention deficit/hyperactivity disorder (ADHD) drugs from 2006 to 2009. METHOD: A total population cohort of all individuals aged 6-45 years, alive and registered as residents in Sweden during any calendar year from 2006 to 2009 (N = 5 149 791) included 41 700 patients dispensed with an ADHD drug (methylphenidate, atomoxetine, amphetamine, or dexamphetamine). The dispensing prevalence was calculated for each year, stratified on sex and age. A longitudinal analysis was also performed to compare the rates of treatment discontinuation across the strata. RESULTS: The dispensing prevalence increased from 2.93 per 1000 in 2006 to 6.98 in 2009 (PR = 2.38, 95% CI = 2.34-2.43). The prevalence ratio (PR) was 3.40 for adults, 22-45 years old; 2.41 for adolescents, 15-21 years old; and 1.90 for children aged 6-14. The increase was also greater in women than in men (PR = 2.92 vs. 2.19). Patients aged 15-21 were the most likely to discontinue treatment; after 3 years and 11 months, 27% of those patients were still under treatment. CONCLUSION: From 2006 to 2009, the number of prescriptions dispensed for ADHD drugs increased substantially. The rate of treatment discontinuation in the age interval 15-21 is higher than expected considering the persistence rates of the disorder.
OBJECTIVE: To explore the prevalence and discontinuation of dispensed medications for attention deficit/hyperactivity disorder (ADHD) drugs from 2006 to 2009. METHOD: A total population cohort of all individuals aged 6-45 years, alive and registered as residents in Sweden during any calendar year from 2006 to 2009 (N = 5 149 791) included 41 700 patients dispensed with an ADHD drug (methylphenidate, atomoxetine, amphetamine, or dexamphetamine). The dispensing prevalence was calculated for each year, stratified on sex and age. A longitudinal analysis was also performed to compare the rates of treatment discontinuation across the strata. RESULTS: The dispensing prevalence increased from 2.93 per 1000 in 2006 to 6.98 in 2009 (PR = 2.38, 95% CI = 2.34-2.43). The prevalence ratio (PR) was 3.40 for adults, 22-45 years old; 2.41 for adolescents, 15-21 years old; and 1.90 for children aged 6-14. The increase was also greater in women than in men (PR = 2.92 vs. 2.19). Patients aged 15-21 were the most likely to discontinue treatment; after 3 years and 11 months, 27% of those patients were still under treatment. CONCLUSION: From 2006 to 2009, the number of prescriptions dispensed for ADHD drugs increased substantially. The rate of treatment discontinuation in the age interval 15-21 is higher than expected considering the persistence rates of the disorder.
Authors: Jennifer E Enns; Jason R Randall; Mark Smith; Dan Chateau; Carole Taylor; Marni Brownell; James M Bolton; Elaine Burland; Alan Katz; Laurence Y Katz; Nathan C Nickel Journal: Can J Psychiatry Date: 2017-02-01 Impact factor: 4.356
Authors: Krista F Huybrechts; Gabriella Bröms; Lotte Brix Christensen; Kristjana Einarsdóttir; Anders Engeland; Kari Furu; Mika Gissler; Sonia Hernandez-Diaz; Pär Karlsson; Øystein Karlstad; Helle Kieler; Anna-Maria Lahesmaa-Korpinen; Helen Mogun; Mette Nørgaard; Johan Reutfors; Henrik Toft Sørensen; Helga Zoega; Brian T Bateman Journal: JAMA Psychiatry Date: 2018-02-01 Impact factor: 21.596
Authors: Yi Lu; Arvid Sjölander; Martin Cederlöf; Brian M D'Onofrio; Catarina Almqvist; Henrik Larsson; Paul Lichtenstein Journal: JAMA Psychiatry Date: 2017-08-01 Impact factor: 21.596
Authors: M Bink; G J M van Boxtel; A Popma; I L Bongers; A J M Denissen; Ch van Nieuwenhuizen Journal: Eur Child Adolesc Psychiatry Date: 2014-11-06 Impact factor: 4.785
Authors: Zheng Chang; Paul Lichtenstein; Brian M D'Onofrio; Arvid Sjölander; Henrik Larsson Journal: JAMA Psychiatry Date: 2014-03 Impact factor: 21.596